These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12907507)

  • 41. Australian regulator insists on greater transparency of industry payments to doctors.
    Coopes A
    BMJ; 2014 Oct; 349():g6335. PubMed ID: 25331811
    [No Abstract]   [Full Text] [Related]  

  • 42. Drug firm conflicting interests. Quis custodiet ipsos custodes?
    Whitmarsh JR
    BMJ; 2009 Dec; 339():b5657. PubMed ID: 20044406
    [No Abstract]   [Full Text] [Related]  

  • 43. GAVI's Advance Market Commitment.
    Schwalbe N; El-Ziq I
    Lancet; 2010 Feb; 375(9715):638-9. PubMed ID: 20171398
    [No Abstract]   [Full Text] [Related]  

  • 44. The drug industry and medical professionalism.
    Tattersall M; Kerridge I
    Lancet; 2006 Jan; 367(9504):28. PubMed ID: 16399149
    [No Abstract]   [Full Text] [Related]  

  • 45. [The influence of the pharmaceutical industry in patient organisations].
    Vermeulen M; Bouma J
    Ned Tijdschr Geneeskd; 2007 Nov; 151(44):2432-4. PubMed ID: 18064861
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Industry and medicine: conflicting interests and the power of money.
    Popovsky MA; Garcia N
    Transfusion; 2007 Jun; 47(6):1098-9. PubMed ID: 17524103
    [No Abstract]   [Full Text] [Related]  

  • 47. Must an interest be a conflict?
    Lyles A
    Clin Ther; 2005 Mar; 27(3):344-5. PubMed ID: 15878388
    [No Abstract]   [Full Text] [Related]  

  • 48. Medicine's lottery losers: it could be you.
    Lancet; 1995 Aug; 346(8972):387. PubMed ID: 7623563
    [No Abstract]   [Full Text] [Related]  

  • 49. Funding health advocacy.
    Issue Brief (Grantmakers Health); 2005 Feb; (21):1-35. PubMed ID: 15779145
    [No Abstract]   [Full Text] [Related]  

  • 50. [Sponsorship of medical congresses, workshops and symposia by pharmaceutical companies].
    Warntjen M
    Pathologe; 2010 Mar; 31(2):157-61. PubMed ID: 20198463
    [No Abstract]   [Full Text] [Related]  

  • 51. AstraZeneca hires top US cancer doctor who resigned over undisclosed pharma links.
    Dyer O
    BMJ; 2019 Jan; 364():l205. PubMed ID: 30642890
    [No Abstract]   [Full Text] [Related]  

  • 52. "Natural ground" for medical research charities: public and patient involvement in research funding.
    Petit-Zeman S; Philpots E; Denegri S
    J Ambul Care Manage; 2010; 33(3):249-56. PubMed ID: 20539152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 'Interests' in medicine and the inadequacy of disclosure.
    Kerridge I
    Aust N Z J Psychiatry; 2012 Jun; 46(6):501-3. PubMed ID: 22679203
    [No Abstract]   [Full Text] [Related]  

  • 54. Doctors and drug companies.
    Lambert LA
    N Engl J Med; 2005 Feb; 352(7):733-4; author reply 733-4. PubMed ID: 15716575
    [No Abstract]   [Full Text] [Related]  

  • 55. Global Fund needs to address conflict of interest.
    Gilmore AB; Fooks G
    Bull World Health Organ; 2012 Jan; 90(1):71-2. PubMed ID: 22271969
    [No Abstract]   [Full Text] [Related]  

  • 56. Transparency of funding of patient groups is mandatory but is not enough.
    Colombo C; Mosconi P
    BMJ; 2014 Oct; 349():g6301. PubMed ID: 25336118
    [No Abstract]   [Full Text] [Related]  

  • 57. Is disclosure of potential conflicts of interest in medicine and public health sufficient to increase transparency and decrease corruption?
    Spelsberg A; Martiny A; Schoenhoefer PS;
    J Epidemiol Community Health; 2009 Aug; 63(8):603-5. PubMed ID: 19596840
    [No Abstract]   [Full Text] [Related]  

  • 58. Research appropriate for support by nongovernmental organizations.
    Guthrie D
    Proc R Soc Med; 1974 Oct; 67(10):1015-8. PubMed ID: 4427883
    [No Abstract]   [Full Text] [Related]  

  • 59. Conflict of interest policies: preserving the public trust.
    Golden RN; Grossman JE
    WMJ; 2009 Feb; 108(1):61-2. PubMed ID: 19326639
    [No Abstract]   [Full Text] [Related]  

  • 60. Drug firm conflicting interests. If only WHI was done well.
    Stevenson JC; Hodis HN; Pickar JH; Lobo RA
    BMJ; 2010 Feb; 340():c591. PubMed ID: 20160317
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.